search
Back to results

A Safety and Efficacy Study of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment

Primary Purpose

Multiple Sclerosis, Walking Impairment

Status
Completed
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
ADS-5102, 274 mg
Sponsored by
Adamas Pharmaceuticals, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Multiple Sclerosis

Eligibility Criteria

18 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Signed a current IRB-approved informed consent form
  • Successful completion of a prior double blind study of ADS-5102 in patients with MS walking impairment.

Exclusion Criteria:

  • Based on the judgment of the investigator or Medical Monitor, participation in the study would jeopardize the safety of the subject.
  • If female, is pregnant or lactating
  • If a sexually active female, is not surgically sterile or at least 2 years post-menopausal, or does not agree to utilize a highly effective hormonal method of contraception (an IUD, or vasectomized male partner is also acceptable), in combination with a barrier method, from baseline through at least 4 weeks after the completion of study treatment. If a sexually active male, does not agree to utilize condoms from screening through at least 4 weeks after the completion of study treatment.
  • Anticipated treatment with any amantadine formulation other than ADS-5102
  • Planned participation in another interventional clinical trial

Sites / Locations

  • Adamas Clinical Site
  • Adamas Clinical Site
  • Adamas Clinical Site
  • Adamas Clinical Site
  • Adamas Clinical Site
  • Adamas Clinical Site
  • Adamas Clinical Site
  • Adamas Clinical Site
  • Adamas Clinical Site
  • Adamas Clinical Site
  • Adamas Clinical Site
  • Adamas Clinical Site
  • Adamas Clinical Site
  • Adamas Clinical Site
  • Adamas Clinical Site
  • Adamas Clinical Site
  • Adamas Clinical Site
  • Adamas Clinical Site
  • Adamas Clinical Site
  • Adamas Clinical Site
  • Adamas Clinical Site
  • Adamas Clinical Site
  • Adamas Clinical Site
  • Adamas Clinical Site
  • Adamas Clinical Site
  • Adamas Clinical Site
  • Adamas Clinical Site
  • Adamas Clinical Site
  • Adamas Clinical Site
  • Adamas Clinical Site
  • Adamas Clinical Site
  • Adamas Clinical Site
  • Adamas Clinical Site
  • Adamas Clinical Site
  • Adamas Clinical Site
  • Adamas Clinical Site
  • Adamas Clinical Site
  • Adamas Clinical Site
  • Adamas Clinical Site
  • Adamas Clinical Site
  • Adamas Clinical Site
  • Adamas Clinical Site
  • Adamas Clinical Site
  • Adamas Clinical Site
  • Adamas Clinical Site
  • Adamas Clinical Site
  • Adamas Clinical Site
  • Adamas Clinical Site
  • Adamas Clinical Site
  • Adamas Clinical Site
  • Adamas Clinical Site
  • Adamas Clinical Site
  • Adamas Clinical Site
  • Adamas Clinical Site
  • Adamas Clinical Site
  • Adamas Clinical Site
  • Adamas Clinical Site
  • Adamas Clinical Site
  • Adamas Clinical Site
  • Adamas Clinical Site
  • Adamas Clinical Site
  • Adamas Clinical Site
  • Adamas Clinical Site
  • Adamas Clinical Site
  • Adamas Clinical Site
  • Adamas Clinical Site
  • Adamas Clinical Site
  • Adamas Clinical Site
  • Adamas Clinical Site
  • Adamas Clinical Site
  • Adamas Clinical Site
  • Adamas Clinical Site
  • Adamas Clinical Site
  • Adamas Clinical Site
  • Adamas Clinical Site
  • Adamas Clinical Site
  • Adamas Clinical Site
  • Adamas Clinical Site
  • Adamas Clinical Site
  • Adamas Clinical Site
  • Adamas Clinical Site
  • Adamas Clinical Site
  • Adamas Clinical Site
  • Adamas Clinical Site
  • Adamas Clinical Site
  • Adamas Clinical Site
  • Adamas Clinical Site
  • Adamas Clinical Site
  • Adamas Clinical Site
  • Adamas Clinical Site
  • Adamas Clinical Site
  • Adamas Clinical Site

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

ADS-5102, 274 mg

Arm Description

274 mg ADS-5102, administered once daily at bedtime for up to 52 weeks

Outcomes

Primary Outcome Measures

Number of Patients With Adverse Events
The incidence of treatment-emergent adverse events was used as the measure for long-term safety and tolerability of ADS-5102.

Secondary Outcome Measures

Timed 25-Foot Walk (Feet/Second) (Baseline Value)
The timed 25-foot walk is a measure of lower extremity function. The subject is directed to a clearly marked 25-foot course and is instructed to walk 25 feet as quickly as possible, but safely. The task is immediately administered again by having the subject walk back the same distance. The result is reported as speed (feet per second). Improvement is indicated by an increase in speed.
Timed 25-Foot Walk (Feet/Second) (Week 24 Value)
The timed 25-foot walk is a measure of lower extremity function. The subject is directed to a clearly marked 25-foot course and is instructed to walk 25 feet as quickly as possible, but safely. The task is immediately administered again by having the subject walk back the same distance. The result is reported as speed (feet per second). Improvement is indicated by an increase in speed.
Timed 25-Foot Walk (Feet/Second) (Week 52 Value)
The timed 25-foot walk is a measure of lower extremity function. The subject is directed to a clearly marked 25-foot course and is instructed to walk 25 feet as quickly as possible, but safely. The task is immediately administered again by having the subject walk back the same distance. The result is reported as speed (feet per second). Improvement is indicated by an increase in speed.
Timed up and go (Baseline Value)
The "timed up and go" is a measure of lower extremity strength, balance, and coordination. The subject stands up from a chair, walks 3 meters then turns around and walks back to the chair to sit down. The result is reported in seconds. Improvement is indicated by negative change scores.
Timed up and go (Week 24 Value)
The "timed up and go" is a measure of lower extremity strength, balance, and coordination. The subject stands up from a chair, walks 3 meters then turns around and walks back to the chair to sit down. The result is reported in seconds. Improvement is indicated by negative change scores.
Timed up and go (Week 52 Value)
The "timed up and go" is a measure of lower extremity strength, balance, and coordination. The subject stands up from a chair, walks 3 meters then turns around and walks back to the chair to sit down. The result is reported in seconds. Improvement is indicated by negative change scores.
2-Minute Walk Test (Baseline Value)
The 2-Minute Walk test is a measure of lower extremity function. The subject is instructed to walk as far as possible in 2 minutes, and the distance is measured in meters. Improvement is indicated by positive change scores.
2-Minute Walk Test (Week 24 Value)
The 2-Minute Walk test is a measure of lower extremity function. The subject is instructed to walk as far as possible in 2 minutes, and the distance is measured in meters. Improvement is indicated by positive change scores.
2-Minute Walk Test (Week 52 Value)
The 2-Minute Walk test is a measure of lower extremity function. The subject is instructed to walk as far as possible in 2 minutes, and the distance is measured in meters. Improvement is indicated by positive change scores.

Full Information

First Posted
May 22, 2018
Last Updated
January 12, 2022
Sponsor
Adamas Pharmaceuticals, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT03567057
Brief Title
A Safety and Efficacy Study of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment
Official Title
A Multicenter, Open-Label Safety and Efficacy Study of ADS-5102 Amantadine Extended Release Capsules in Patients With Multiple Sclerosis and Walking Impairment
Study Type
Interventional

2. Study Status

Record Verification Date
January 2022
Overall Recruitment Status
Completed
Study Start Date
July 18, 2018 (Actual)
Primary Completion Date
November 17, 2020 (Actual)
Study Completion Date
April 18, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Adamas Pharmaceuticals, Inc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This study assessed the long-term safety and tolerability of ADS-5102 in subjects with MS and walking impairment who had completed the double-blind, placebo-controlled study of ADS-5102 in subjects with MS (ADS-AMT-301).
Detailed Description
This was a multicenter, open-label study of ADS-5102 (amantadine) extended-release capsules in subjects with MS and walking impairment who completed study drug treatment for 16 weeks and completed a Week 16 visit in Study ADS-AMT-MS301. All enrolled subjects were to receive ADS-5102 at 137 mg for the first week, 205.5 mg for the second week, and 274 mg for the remainder of the 52-week open-label treatment period. Subjects returned to the clinic for safety and efficacy assessments at Weeks 4, 24, and 52. In addition, a telephone visit for safety assessments was conducted at Week 2 and Week 38. Subjects who withdrew from the study prior to completion of the Week 52 visit had an early termination (ET) visit that included safety and efficacy assessments. Subjects who completed 52 weeks of open-label treatment had a final visit for post-treatment safety follow-up and efficacy assessment at Week 54. All study visits and efficacy assessments were to be scheduled to occur at approximately the same time of day for each individual subject. Each subject's efficacy assessment was to be performed by the same clinical rater, if possible.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Multiple Sclerosis, Walking Impairment

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
424 (Actual)

8. Arms, Groups, and Interventions

Arm Title
ADS-5102, 274 mg
Arm Type
Experimental
Arm Description
274 mg ADS-5102, administered once daily at bedtime for up to 52 weeks
Intervention Type
Drug
Intervention Name(s)
ADS-5102, 274 mg
Other Intervention Name(s)
amantadine extended release
Intervention Description
Oral capsules
Primary Outcome Measure Information:
Title
Number of Patients With Adverse Events
Description
The incidence of treatment-emergent adverse events was used as the measure for long-term safety and tolerability of ADS-5102.
Time Frame
Through study completion, an average of 1 year.
Secondary Outcome Measure Information:
Title
Timed 25-Foot Walk (Feet/Second) (Baseline Value)
Description
The timed 25-foot walk is a measure of lower extremity function. The subject is directed to a clearly marked 25-foot course and is instructed to walk 25 feet as quickly as possible, but safely. The task is immediately administered again by having the subject walk back the same distance. The result is reported as speed (feet per second). Improvement is indicated by an increase in speed.
Time Frame
Baseline
Title
Timed 25-Foot Walk (Feet/Second) (Week 24 Value)
Description
The timed 25-foot walk is a measure of lower extremity function. The subject is directed to a clearly marked 25-foot course and is instructed to walk 25 feet as quickly as possible, but safely. The task is immediately administered again by having the subject walk back the same distance. The result is reported as speed (feet per second). Improvement is indicated by an increase in speed.
Time Frame
24 weeks
Title
Timed 25-Foot Walk (Feet/Second) (Week 52 Value)
Description
The timed 25-foot walk is a measure of lower extremity function. The subject is directed to a clearly marked 25-foot course and is instructed to walk 25 feet as quickly as possible, but safely. The task is immediately administered again by having the subject walk back the same distance. The result is reported as speed (feet per second). Improvement is indicated by an increase in speed.
Time Frame
52 weeks
Title
Timed up and go (Baseline Value)
Description
The "timed up and go" is a measure of lower extremity strength, balance, and coordination. The subject stands up from a chair, walks 3 meters then turns around and walks back to the chair to sit down. The result is reported in seconds. Improvement is indicated by negative change scores.
Time Frame
Baseline
Title
Timed up and go (Week 24 Value)
Description
The "timed up and go" is a measure of lower extremity strength, balance, and coordination. The subject stands up from a chair, walks 3 meters then turns around and walks back to the chair to sit down. The result is reported in seconds. Improvement is indicated by negative change scores.
Time Frame
24 weeks
Title
Timed up and go (Week 52 Value)
Description
The "timed up and go" is a measure of lower extremity strength, balance, and coordination. The subject stands up from a chair, walks 3 meters then turns around and walks back to the chair to sit down. The result is reported in seconds. Improvement is indicated by negative change scores.
Time Frame
52 weeks
Title
2-Minute Walk Test (Baseline Value)
Description
The 2-Minute Walk test is a measure of lower extremity function. The subject is instructed to walk as far as possible in 2 minutes, and the distance is measured in meters. Improvement is indicated by positive change scores.
Time Frame
Baseline
Title
2-Minute Walk Test (Week 24 Value)
Description
The 2-Minute Walk test is a measure of lower extremity function. The subject is instructed to walk as far as possible in 2 minutes, and the distance is measured in meters. Improvement is indicated by positive change scores.
Time Frame
24 weeks
Title
2-Minute Walk Test (Week 52 Value)
Description
The 2-Minute Walk test is a measure of lower extremity function. The subject is instructed to walk as far as possible in 2 minutes, and the distance is measured in meters. Improvement is indicated by positive change scores.
Time Frame
52 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Signed a current IRB-approved informed consent form Successful completion of a prior double blind study of ADS-5102 in patients with MS walking impairment. Exclusion Criteria: Based on the judgment of the investigator or Medical Monitor, participation in the study would jeopardize the safety of the subject. If female, is pregnant or lactating If a sexually active female, is not surgically sterile or at least 2 years post-menopausal, or does not agree to utilize a highly effective hormonal method of contraception (an IUD, or vasectomized male partner is also acceptable), in combination with a barrier method, from baseline through at least 4 weeks after the completion of study treatment. If a sexually active male, does not agree to utilize condoms from screening through at least 4 weeks after the completion of study treatment. Anticipated treatment with any amantadine formulation other than ADS-5102 Planned participation in another interventional clinical trial
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Clinical Trials Chief Medical Officer, MD
Organizational Affiliation
Adamas Pharmaceuticals, Inc.
Official's Role
Study Director
Facility Information:
Facility Name
Adamas Clinical Site
City
Cullman
State/Province
Alabama
ZIP/Postal Code
35058
Country
United States
Facility Name
Adamas Clinical Site
City
Phoenix
State/Province
Arizona
ZIP/Postal Code
85018
Country
United States
Facility Name
Adamas Clinical Site
City
Phoenix
State/Province
Arizona
ZIP/Postal Code
85032
Country
United States
Facility Name
Adamas Clinical Site
City
Tucson
State/Province
Arizona
ZIP/Postal Code
85704
Country
United States
Facility Name
Adamas Clinical Site
City
Carlsbad
State/Province
California
ZIP/Postal Code
92011
Country
United States
Facility Name
Adamas Clinical Site
City
Fresno
State/Province
California
ZIP/Postal Code
93710
Country
United States
Facility Name
Adamas Clinical Site
City
Fullerton
State/Province
California
ZIP/Postal Code
92835
Country
United States
Facility Name
Adamas Clinical Site
City
Long Beach
State/Province
California
ZIP/Postal Code
90806
Country
United States
Facility Name
Adamas Clinical Site
City
Newport Beach
State/Province
California
ZIP/Postal Code
92663
Country
United States
Facility Name
Adamas Clinical Site
City
Sacramento
State/Province
California
ZIP/Postal Code
95817
Country
United States
Facility Name
Adamas Clinical Site
City
Aurora
State/Province
Colorado
ZIP/Postal Code
80045
Country
United States
Facility Name
Adamas Clinical Site
City
Colorado Springs
State/Province
Colorado
ZIP/Postal Code
80907
Country
United States
Facility Name
Adamas Clinical Site
City
Denver
State/Province
Colorado
ZIP/Postal Code
800209
Country
United States
Facility Name
Adamas Clinical Site
City
Fort Collins
State/Province
Colorado
ZIP/Postal Code
80528
Country
United States
Facility Name
Adamas Clinical Site
City
Fairfield
State/Province
Connecticut
ZIP/Postal Code
06824
Country
United States
Facility Name
Adamas Clinical Site
City
New London
State/Province
Connecticut
ZIP/Postal Code
06320
Country
United States
Facility Name
Adamas Clinical Site
City
Washington
State/Province
District of Columbia
ZIP/Postal Code
20007
Country
United States
Facility Name
Adamas Clinical Site
City
Maitland
State/Province
Florida
ZIP/Postal Code
32751
Country
United States
Facility Name
Adamas Clinical Site
City
Miami
State/Province
Florida
ZIP/Postal Code
33136
Country
United States
Facility Name
Adamas Clinical Site
City
Miami
State/Province
Florida
ZIP/Postal Code
33176
Country
United States
Facility Name
Adamas Clinical Site
City
Naples
State/Province
Florida
ZIP/Postal Code
34105
Country
United States
Facility Name
Adamas Clinical Site
City
Orlando
State/Province
Florida
ZIP/Postal Code
32806
Country
United States
Facility Name
Adamas Clinical Site
City
Ormond Beach
State/Province
Florida
ZIP/Postal Code
32174
Country
United States
Facility Name
Adamas Clinical Site
City
Palm Coast
State/Province
Florida
ZIP/Postal Code
32164
Country
United States
Facility Name
Adamas Clinical Site
City
Port Charlotte
State/Province
Florida
ZIP/Postal Code
33952
Country
United States
Facility Name
Adamas Clinical Site
City
Saint Petersburg
State/Province
Florida
ZIP/Postal Code
33713
Country
United States
Facility Name
Adamas Clinical Site
City
Sarasota
State/Province
Florida
ZIP/Postal Code
34233
Country
United States
Facility Name
Adamas Clinical Site
City
Tampa
State/Province
Florida
ZIP/Postal Code
33609
Country
United States
Facility Name
Adamas Clinical Site
City
Vero Beach
State/Province
Florida
ZIP/Postal Code
32960
Country
United States
Facility Name
Adamas Clinical Site
City
Atlanta
State/Province
Georgia
ZIP/Postal Code
30309
Country
United States
Facility Name
Adamas Clinical Site
City
Savannah
State/Province
Georgia
ZIP/Postal Code
31406
Country
United States
Facility Name
Adamas Clinical Site
City
Northbrook
State/Province
Illinois
ZIP/Postal Code
60062
Country
United States
Facility Name
Adamas Clinical Site
City
Indianapolis
State/Province
Indiana
ZIP/Postal Code
46256
Country
United States
Facility Name
Adamas Clinical Site
City
Kansas City
State/Province
Kansas
ZIP/Postal Code
66103
Country
United States
Facility Name
Adamas Clinical Site
City
Lenexa
State/Province
Kansas
ZIP/Postal Code
66214
Country
United States
Facility Name
Adamas Clinical Site
City
Overland Park
State/Province
Kansas
ZIP/Postal Code
66212
Country
United States
Facility Name
Adamas Clinical Site
City
Burlington
State/Province
Massachusetts
ZIP/Postal Code
01805
Country
United States
Facility Name
Adamas Clinical Site
City
Foxboro
State/Province
Massachusetts
ZIP/Postal Code
02035
Country
United States
Facility Name
Adamas Clinical Site
City
Worcester
State/Province
Massachusetts
ZIP/Postal Code
01655
Country
United States
Facility Name
Adamas Clinical Site
City
Detroit
State/Province
Michigan
ZIP/Postal Code
42801
Country
United States
Facility Name
Adamas Clinical Site
City
Farmington Hills
State/Province
Michigan
ZIP/Postal Code
48334
Country
United States
Facility Name
Adamas Clinical Site
City
Golden Valley
State/Province
Minnesota
ZIP/Postal Code
55422
Country
United States
Facility Name
Adamas Clinical Site
City
Kansas City
State/Province
Missouri
ZIP/Postal Code
64111
Country
United States
Facility Name
Adamas Clinical Site
City
Saint Louis
State/Province
Missouri
ZIP/Postal Code
63110
Country
United States
Facility Name
Adamas Clinical Site
City
Great Falls
State/Province
Montana
ZIP/Postal Code
59405
Country
United States
Facility Name
Adamas Clinical Site
City
Lincoln
State/Province
Nebraska
ZIP/Postal Code
68506
Country
United States
Facility Name
Adamas Clinical Site
City
Omaha
State/Province
Nebraska
ZIP/Postal Code
68105
Country
United States
Facility Name
Adamas Clinical Site
City
Las Vegas
State/Province
Nevada
ZIP/Postal Code
89106
Country
United States
Facility Name
Adamas Clinical Site
City
Albuquerque
State/Province
New Mexico
ZIP/Postal Code
87106
Country
United States
Facility Name
Adamas Clinical Site
City
Amherst
State/Province
New York
ZIP/Postal Code
14226
Country
United States
Facility Name
Adamas Clinical Site
City
Lake Success
State/Province
New York
ZIP/Postal Code
11042
Country
United States
Facility Name
Adamas Clinical Site
City
New York
State/Province
New York
ZIP/Postal Code
10029
Country
United States
Facility Name
Adamas Clinical Site
City
Patchogue
State/Province
New York
ZIP/Postal Code
11772
Country
United States
Facility Name
Adamas Clinical Site
City
Plainview
State/Province
New York
ZIP/Postal Code
11803
Country
United States
Facility Name
Adamas Clinical Site
City
Rochester
State/Province
New York
ZIP/Postal Code
14642
Country
United States
Facility Name
Adamas Clinical Site
City
Staten Island
State/Province
New York
ZIP/Postal Code
10306
Country
United States
Facility Name
Adamas Clinical Site
City
Charlotte
State/Province
North Carolina
ZIP/Postal Code
28204
Country
United States
Facility Name
Adamas Clinical Site
City
Raleigh
State/Province
North Carolina
ZIP/Postal Code
27607
Country
United States
Facility Name
Adamas Clinical Site
City
Centerville
State/Province
Ohio
ZIP/Postal Code
45459
Country
United States
Facility Name
Adamas Clinical Site
City
Cleveland
State/Province
Ohio
ZIP/Postal Code
44195
Country
United States
Facility Name
Adamas Clinical Site
City
Columbus
State/Province
Ohio
ZIP/Postal Code
43214
Country
United States
Facility Name
Adamas Clinical Site
City
Oklahoma City
State/Province
Oklahoma
ZIP/Postal Code
73104
Country
United States
Facility Name
Adamas Clinical Site
City
Portland
State/Province
Oregon
ZIP/Postal Code
97213
Country
United States
Facility Name
Adamas Clinical Site
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19140
Country
United States
Facility Name
Adamas Clinical Site
City
Charleston
State/Province
South Carolina
ZIP/Postal Code
29406
Country
United States
Facility Name
Adamas Clinical Site
City
Greer
State/Province
South Carolina
ZIP/Postal Code
29650
Country
United States
Facility Name
Adamas Clinical Site
City
Rock Hill
State/Province
South Carolina
ZIP/Postal Code
29732
Country
United States
Facility Name
Adamas Clinical Site
City
Spartanburg
State/Province
South Carolina
ZIP/Postal Code
29307
Country
United States
Facility Name
Adamas Clinical Site
City
Cordova
State/Province
Tennessee
ZIP/Postal Code
38018
Country
United States
Facility Name
Adamas Clinical Site
City
Franklin
State/Province
Tennessee
ZIP/Postal Code
37064
Country
United States
Facility Name
Adamas Clinical Site
City
Johnson City
State/Province
Tennessee
ZIP/Postal Code
37604
Country
United States
Facility Name
Adamas Clinical Site
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
Facility Name
Adamas Clinical Site
City
Houston
State/Province
Texas
ZIP/Postal Code
77074
Country
United States
Facility Name
Adamas Clinical Site
City
Lubbock
State/Province
Texas
ZIP/Postal Code
79410
Country
United States
Facility Name
Adamas Clinical Site
City
Round Rock
State/Province
Texas
ZIP/Postal Code
78681
Country
United States
Facility Name
Adamas Clinical Site
City
Salt Lake City
State/Province
Utah
ZIP/Postal Code
84103
Country
United States
Facility Name
Adamas Clinical Site
City
Newport News
State/Province
Virginia
ZIP/Postal Code
23601
Country
United States
Facility Name
Adamas Clinical Site
City
Norfolk
State/Province
Virginia
ZIP/Postal Code
23502
Country
United States
Facility Name
Adamas Clinical Site
City
Kirkland
State/Province
Washington
ZIP/Postal Code
98034
Country
United States
Facility Name
Adamas Clinical Site
City
Seattle
State/Province
Washington
ZIP/Postal Code
98122
Country
United States
Facility Name
Adamas Clinical Site
City
Seattle
State/Province
Washington
ZIP/Postal Code
98191
Country
United States
Facility Name
Adamas Clinical Site
City
Milwaukee
State/Province
Wisconsin
ZIP/Postal Code
53215
Country
United States
Facility Name
Adamas Clinical Site
City
Edmonton
State/Province
Alberta
ZIP/Postal Code
T6G 2G3
Country
Canada
Facility Name
Adamas Clinical Site
City
Lethbridge
State/Province
Alberta
ZIP/Postal Code
T1J 0N9
Country
Canada
Facility Name
Adamas Clinical Site
City
Burnaby
State/Province
Brithis Columbia
ZIP/Postal Code
V5G 2X6
Country
Canada
Facility Name
Adamas Clinical Site
City
Vancouver
State/Province
British Columbia
ZIP/Postal Code
V6T 2B5
Country
Canada
Facility Name
Adamas Clinical Site
City
Hamilton
State/Province
Ontario
ZIP/Postal Code
L8L 2X2
Country
Canada
Facility Name
Adamas Clinical Site
City
London
State/Province
Ontario
ZIP/Postal Code
N6A 5A5
Country
Canada
Facility Name
Adamas Clinical Site
City
Ottawa
State/Province
Ontario
ZIP/Postal Code
K1H 8L6
Country
Canada
Facility Name
Adamas Clinical Site
City
Greenfield Park
State/Province
Quebec
ZIP/Postal Code
J4V 2J2
Country
Canada
Facility Name
Adamas Clinical Site
City
Montréal
State/Province
Quebec
ZIP/Postal Code
H3A 2B4
Country
Canada
Facility Name
Adamas Clinical Site
City
Québec City
State/Province
Quebec
ZIP/Postal Code
G1J 1Z4
Country
Canada

12. IPD Sharing Statement

Learn more about this trial

A Safety and Efficacy Study of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment

We'll reach out to this number within 24 hrs